{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T11:23:50Z","timestamp":1793618630185,"version":"4.5.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>The triglyceride-rich apoB lipoprotein particles make up a minority of the apoB particles in plasma. They vary in size, in lipid, and in protein content. Most are small enough to enter the arterial wall and therefore most are atherogenic. But how important a contribution TRL particles make to the total risk created by the apoB lipoproteins remains controversial. A recent Mendelian randomization analysis determined that the cardiovascular risk related to the cholesterol within these apoB particles--the TRL cholesterol--was greater than--and independent of--the risk related to apoB. If correct, these observations have major clinical significance.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Accordingly, we have analyzed these results in detail. In our view, the independent strength of the association between TRL cholesterol and apoB with cardiovascular risk seems inconsistent with the biological connections between apoB and cholesterol as integral and highly correlated constituents of apoB particles. These results are also inconsistent with other lines of evidence such as the results of the fibrate randomized clinical trials. Moreover, we are also concerned with other aspects of the analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>We do not regard the issue as settled. However, this enquiry has led us to a fuller understanding of the determinants of the cholesterol content of the TRL apoB particles and the complex processing of cholesterol amongst the plasma lipoproteins.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mol.0000000000000905","type":"journal-article","created":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T14:00:09Z","timestamp":1695996009000},"page":"259-266","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Triglyceride-rich lipoprotein cholesterol and cardiovascular risk"],"prefix":"10.1097","volume":"34","author":[{"given":"Selin","family":"Bilgic","sequence":"first","affiliation":[{"name":"Mike and Valeria Rosenbloom Centre for Cardiovascular Prevention, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan T.","family":"Remaley","sequence":"additional","affiliation":[{"name":"National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan D.","family":"Sniderman","sequence":"additional","affiliation":[{"name":"Mike and Valeria Rosenbloom Centre for Cardiovascular Prevention, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,9,29]]},"reference":[{"key":"R1-20250729","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur Heart J"},{"key":"R2-20250729","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1001\/jama.2018.20045","article-title":"Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease","volume":"321","author":"Ference","year":"2019","journal-title":"JAMA"},{"key":"R3-20250729","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1001\/jamacardio.2019.3780","article-title":"Apolipoprotein B particles and cardiovascular disease: a narrative review","volume":"4","author":"Sniderman","year":"2019","journal-title":"JAMA Cardiol"},{"key":"R4-20250729","first-page":"ehad298","article-title":"Remnant cholesterol in the era of intensive lipid-lowering therapies","author":"Wadstrom","year":"2023","journal-title":"Eur Heart J"},{"key":"R5-20250729","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/MOL.0000000000000875","article-title":"Triglyceride-rich lipoproteins, remnant-cholesterol, and atherosclerotic cardiovascular disease","volume":"34","author":"Ganda","year":"2023","journal-title":"Curr Opin Lipidol"},{"key":"R6-20250729","first-page":"ehad337","article-title":"Triglyceride-rich lipoprotein remnants, low-density lipoproteins, and risk of coronary heart disease: a UK Biobank study","author":"Bjornson","year":"2023","journal-title":"Eur Heart J"},{"key":"R7-20250729","first-page":"ehad330","article-title":"Triglyceride-rich remnant lipoproteins are more atherogenic than LDL per particle: is this important?","author":"Tybjaerg-Hansen","year":"2023","journal-title":"Eur Heart J"},{"key":"R8-20250729","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1161\/CIRCULATIONAHA.119.041149","article-title":"Comparison of conventional lipoprotein tests and apolipoproteins in the prediction of cardiovascular disease","volume":"140","author":"Welsh","year":"2019","journal-title":"Circulation"},{"key":"R9-20250729","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1001\/jamacardio.2021.5083","article-title":"Association of apolipoprotein B-containing lipoproteins and risk of myocardial infarction in individuals with and without atherosclerosis: distinguishing between particle concentration, type, and content","volume":"7","author":"Marston","year":"2022","journal-title":"JAMA Cardiol"},{"key":"R10-20250729","doi-asserted-by":"crossref","first-page":"e1003062","DOI":"10.1371\/journal.pmed.1003062","article-title":"Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: a multivariable Mendelian randomisation analysis","volume":"17","author":"Richardson","year":"2020","journal-title":"PLoS Med"},{"key":"R11-20250729","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S2666-7568(21)00086-6","article-title":"Effects of apolipoprotein B on lifespan and risks of major diseases including type 2 diabetes: a mendelian randomisation analysis using outcomes in first-degree relatives","volume":"2","author":"Richardson","year":"2021","journal-title":"Lancet Healthy Longev"},{"key":"R12-20250729","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1093\/ije\/dyaa216","article-title":"High-throughput multivariable Mendelian randomization analysis prioritizes apolipoprotein B as key lipid risk factor for coronary artery disease","volume":"50","author":"Zuber","year":"2021","journal-title":"Int J Epidemiol"},{"key":"R13-20250729","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1161\/CIRCULATIONAHA.121.053797","article-title":"Prioritizing the role of major lipoproteins and subfractions as risk factors for peripheral artery disease","volume":"144","author":"Levin","year":"2021","journal-title":"Circulation"},{"key":"R14-20250729","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of anacetrapib in patients with atherosclerotic vascular disease","volume":"377","author":"Group","year":"2017","journal-title":"N Engl J Med"},{"key":"R15-20250729","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"Das Pradhan","year":"2022","journal-title":"N Engl J Med"},{"key":"R16-20250729","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1194\/jlr.R082271","article-title":"Hypertriglyceridemia and cardiovascular risk: a cautionary note about metabolic confounding","volume":"59","author":"Sniderman","year":"2018","journal-title":"J Lipid Res"},{"key":"R17-20250729","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1001\/jamacardio.2020.0013","article-title":"A new equation for calculation of low-density lipoprotein cholesterol in patients with normolipidemia and\/or hypertriglyceridemia","volume":"5","author":"Sampson","year":"2020","journal-title":"JAMA Cardiol"},{"key":"R18-20250729","doi-asserted-by":"crossref","first-page":"e030405","DOI":"10.1161\/JAHA.123.030405","article-title":"Standardization of apolipoprotein B, LDL-cholesterol, and non-HDL-cholesterol","volume":"12","author":"Contois","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"R19-20250729","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1373\/clinchem.2009.142810","article-title":"Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures","volume":"56","author":"Miller","year":"2010","journal-title":"Clin Chem"},{"key":"R20-20250729","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/clinchem\/hvac161","article-title":"A translational tool to facilitate use of apolipoprotein B for clinical decision-making","volume":"69","author":"Cole","year":"2023","journal-title":"Clin Chem"},{"key":"R21-20250729","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/0006-291X(78)90691-5","article-title":"Human chylomicron apolipoprotein metabolism","volume":"80","author":"Schaefer","year":"1978","journal-title":"Biochem Biophys Res Commun"},{"key":"R22-20250729","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2023.05.093","article-title":"Is hypertriglyceridemia a reliable indicator of cholesterol-depleted apoB particles?","author":"De Marco","year":"2023","journal-title":"Clin Lipidol"},{"key":"R23-20250729","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1194\/jlr.M500018-JLR200","article-title":"ACAT2 contributes cholesteryl esters to newly secreted VLDL, whereas LCAT adds cholesteryl ester to LDL in mice","volume":"46","author":"Lee","year":"2005","journal-title":"J Lipid Res"},{"key":"R24-20250729","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1373\/clinchem.2018.298026","article-title":"Type III hyperlipoproteinemia: the forgotten, disregarded, neglected, overlooked, ignored but highly atherogenic, and highly treatable dyslipoproteinemia","volume":"65","author":"Sniderman","year":"2019","journal-title":"Clin Chem"},{"key":"R25-20250729","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jacl.2012.04.081","article-title":"Phenotypes of hypertriglyceridemia caused by excess very-low-density lipoprotein","volume":"6","author":"Sniderman","year":"2012","journal-title":"J Clin Lipidol"},{"key":"R26-20250729","doi-asserted-by":"crossref","first-page":"935257","DOI":"10.3389\/fgene.2022.935257","article-title":"Identification of dysbetalipoproteinemia by an enhanced Sampson-NIH equation for very low-density lipoprotein-cholesterol","volume":"13","author":"Sampson","year":"2022","journal-title":"Front Genet"},{"key":"R27-20250729","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.jacc.2022.01.010","article-title":"Key questions about familial hypercholesterolemia: JACC review topic of the week","volume":"79","author":"Sniderman","year":"2022","journal-title":"J Am Coll Cardiol"}],"container-title":["Current Opinion in Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOL.0000000000000905","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T22:05:21Z","timestamp":1753826721000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MOL.0000000000000905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,29]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/mol.0000000000000905","relation":{},"ISSN":["0957-9672","1473-6535"],"issn-type":[{"value":"0957-9672","type":"print"},{"value":"1473-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,29]]}}}